Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Investments: 2009-2013

Historic Long-Term Investments for Ani Pharmaceuticals (ANIP) over the last 3 years, with Mar 2013 value amounting to $3.4 million.

  • Ani Pharmaceuticals' Long-Term Investments changed negligibly% to $3.4 million in Q1 2013 from the same period last year, while for Mar 2013 it was $3.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.4 million for FY2012, which is 0.23% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Long-Term Investments of $3.4 million as of Q1 2013, which was down 0.00% from $3.4 million recorded in Q4 2012.
  • Ani Pharmaceuticals' 5-year Long-Term Investments high stood at $3.6 million for Q4 2009, and its period low was $3.3 million during Q3 2010.
  • Over the past 3 years, Ani Pharmaceuticals' median Long-Term Investments value was $3.4 million (recorded in 2013), while the average stood at $3.4 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Long-Term Investments decreased by 6.07% in 2010, and later rose by 1.97% in 2011.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Long-Term Investments stood at $3.6 million in 2009, then fell by 6.07% to $3.4 million in 2010, then remained steady at $3.4 million in 2011, then grew by 0.23% to $3.4 million in 2012, then remained steady at $3.4 million in 2013.
  • Its last three reported values are $3.4 million in Q1 2013, $3.4 million for Q4 2012, and $3.4 million during Q3 2012.